Mallinckrodt plc Confirms Enrollment of the First Patient in Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Mallinckrodt plc confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the respiratory condition symptomatic sarcoidosis, one of 19 indications.